tbuckley/cabot-search huggingface dataset:
Haploidentical Stem Cell Transplantation with CD3 Depleted Mobilized Peripheral Blood Stem Cell Grafts for Children with Hematologic Malignancies.
Authors: Gregory A. Hale, Kimberly A. Kasow, Kwan Gan, Edwin Horwitz, Joseph P. Woodard, Usman Yusuf, Raymond Barfield, Wing H. Leung, Deo K. Srivastava, Rupert Handgretinger
Journal: Blood (2005)
Generating Multicompartmental 3D Biological Constructs Interfaced through Sequential Injections in Microfluidic Devices
Authors: Giovanni Stefano Ugolini, Roberta Visone, Alberto Redaelli, Matteo Moretti, Marco Rasponi
Journal: Advanced Healthcare Materials (2017)

A novel technique is presented for molding and culturing composite 3D cellular constructs within microfluidic channels. The method is based on the use of removable molding polydimethylsiloxane (PDMS) inserts, which allow to selectively and incrementally generate composite 3D constructs featuring different cell types and/or biomaterials, with a high spatial control. The authors generate constructs made of either stacked hydrogels, with uniform horizontal interfaces, or flanked hydrogels with vertical interfaces. The authors also show how this technique can be employed to create custom‐shaped endothelial barriers and monolayers directly interfaced with 3D cellular constructs. This method dramatically improves the significance of in vitro 3D biological models, enhancing mimicry and enabling for controlled studies of complex biological districts.
All emergency departments must have GP led triage by October
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Every hospital in England must have a “comprehensive” GP led triage system in emergency departments by October 2017 in a bid to avoid a repeat of the winter crisis that gripped the service this year, NHS leaders have said.

The requirement is one of several “concrete changes” demanded by NHS England’s chief executive, Simon Stevens, and the chief executive of NHS Improvement, Jim Mackey, in a letter sent after the chancellor Philip Hammond’s budget pledge to give the NHS an extra £100m (€115m; $120m) in 2017‑18 to spend on easing pressures in accident and emergency departments.1

Announcing the budget in a speech to the House of Commons on 8 March, the chancellor said, “Experience has shown that onsite GP triage in A&E departments can have a significant and positive impact on A&E waiting times.”

In a joint …
Dual Engineering of Human CD8+ T-Cells with WT1-Specific TCR Gene and Chemokine Receptor Gene Transfer Confers Functionally Strengthened Anti-Cancer Reactivity
Authors: Yukihiro Miyazaki, Hiroshi Fujiwara, Toshiki Ochi, An Jun, Toshiaki Shirakata, Kozo Nagai, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa
Journal: Blood (2010)
Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies
Authors: John T. Walkup
Journal: American Journal of Psychiatry (2017)

Significant controversy surrounds the efficacy of the newer antidepressants for children and adolescents with depression. The controversy largely hinges on meta-analyses of studies that suggest that antidepressants are minimally effective, not effective, or equivalent to placebo. In this review, the author discusses several scientific and clinical complexities that are important to understand in reviewing the antidepressant literature: the strengths and weaknesses of meta-analyses; the scientific and regulatory context for the large number of antidepressant trials in the late 1990s and early 2000s; and the distinction between a negative trial, where the treatment does not demonstrate efficacy, and a failed trial, where methodological problems make it impossible to draw any conclusion about efficacy. It is the premise of this review that meta-analyses that include the large number of industry-sponsored antidepressant trials distort the picture of antidepressant efficacy for teen depression. Industry-sponsored child and adolescent depression trials suffer from a number of implementation challenges and should be considered failed trials that are largely uninformative and not eligible to be included in efficacy meta-analyses. In contrast to the industry-sponsored trials, depression trials funded by the National Institute of Mental Health (NIMH) (N=2) are characterized by many methodological strengths, lower placebo response rates (30%-35%), and meaningful between-group differences (25%-30%) that support antidepressant efficacy. The NIMH-funded trials, taken together with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsessive-compulsive disorder and the anxiety disorders, suggest a broad and important role for antidepressant medications in pediatric internalizing conditions.
BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells
Authors: Baohua Sun, Warren Fiskus, Dyana T Saenz, Stephanie Krieger, Liang Zhang, Simrit Parmar, Michael Wang, Kapil N. Bhalla
Journal: Blood (2015)
Beta-2 Microglobulin and Soluble Interleukin-2 Receptor Serum Levels Correlates with Human Immunodeficiency Virus Associated Non-Hodgkins Lymphoma-Diffuse Large B-Cell Lymphoma (HIV-NHL-DLBCL).
Authors: Eugene McPherson, J. Ng, E. Hazel, P. Tassy
Journal: Blood (2005)
Assessing Factors Associated With Suicide Risk—Reply
Authors: Pearl L. H. Mok, Carsten Bøcker Pedersen, Roger T. Webb
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era
Authors: Irit Avivi, Ariel Zilberlicht, Eldad J Dann, Jacob M. Rowe, Ronit Leiba, Tal Faibish, Rachel Bar-Shalom
Journal: Blood (2011)
Abstract A60: Hyaluronan and cancer cell derived swelling of solid tumors and implications for cancer therapy
Authors: Chrysovalantis Voutouri, Christiana Polydorou, Panagiotis Papageorgis, Triantafyllos Stylianopoulos
Journal: Cancer Research (2017)

Abstract A solid tumor is an aberrant tissue made of cancer cells and a variety of host cells—all embedded in an extracellular matrix—nourished by blood vessels and drained by lymphatic vessels. Rapid tumor growth in the confined space of the host tissue results in the accumulation of mechanical forces within structural components of the tumor, and between the tumor and the host. These forces can shape the tumor microenvironment and determine in large part tumor progression and response to treatment. Despite the important role that mechanical forces play in tumor growth, the contribution of swelling to tumor mechanics remains unexplored. Tumors rich in hyaluronan exhibit a highly negative fixed charge density. Repulsive forces among these negative charges cause swelling of the tumor and development of swelling solid stress. Additionally, fixed negative charges attract free cations from the tumor interstitial space creating an imbalance of ion distribution and a Donnan osmotic fluid pressure. Furthermore, it has been shown that tumor swelling can be produces not only by hyaluronan but also cancer cells swell due to osmotic regulation, which is required for their survival under compressive forces. In this study, we design an experimental set up to measure hyaluronan derived swelling solid stress in two orthotopic breast tumor models of different extracellular matrix composition. We also calculate the Donnan osmotic pressure and the solid stress owing to interactions with the host tissue, utilizing the experimental data and developing a triphasic biomechanical mathematical model. The mathematical model accounts for the fluid and the solid phase of a tumor and the transport of anions and cations. Furthermore, we measure the swelling of cancer cell spheroids under compressive mechanical forces in order to quantify cell derived tumor swelling. We will present data showing that swelling stress contributes significantly to tumor mechanics, whereas Donnan osmotic pressure is negligible. Interestingly, histological analysis revealed a linear correlation between swelling stress and the ratio of hyaluronan to collagen content. Our analysis further suggested an inverse relation of swelling stress to vessel diameter and tumor perfusion. These results provide guidelines for emerging therapeutic strategies that target the tumor microenvironment to alleviate swelling stress and improve perfusion and drug delivery. Citation Format: Chrysovalantis Voutouri, Christiana Polydorou, Panagiotis Papageorgis, Triantafyllos Stylianopoulos. Hyaluronan and cancer cell derived swelling of solid tumors and implications for cancer therapy. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A60.
Successful Peripheral Stem Cell Autologous Engraftment in Skin of a Patient with Severe Dermal Atrophy and Senile Purpura. First Venezuelan Report.
Authors: Jorge I. Herrera-Cepeda, Roger R. Devis-Hazim, Maira L. Urdaneta-Herrera, Glenda R. Marquez-Herrera
Journal: Blood (2007)
Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells
Authors: Joshua M. Gammon, Emily A. Gosselin, Lisa H. Tostanoski, Yu-Chieh Chiu, Xiangbin Zeng, Qin Zeng, Christopher M. Jewell
Journal: Journal of Controlled Release (2017)

An important goal for improving vaccine and immunotherapy technologies is the ability to provide further control over the specific phenotypes of T cells arising from these agents. Along these lines, frequent administration of rapamycin (Rapa), a small molecule inhibitor of the mammalian target of rapamycin (mTOR), exhibits a striking ability to polarize T cells toward central memory phenotypes (TCM), or to suppress immune function, depending on the concentrations and other signals present during administration. TCM exhibit greater plasticity and proliferative capacity than effector memory T cells (TEFF) and, therefore, polarizing vaccine-induced T cells toward TCM is an intriguing strategy to enhance T cell expansion and function against pathogens or tumors. Here we combined biodegradable microparticles encapsulating Rapa (Rapa MPs) with vaccines composed of soluble peptide antigens and molecular adjuvants to test if this approach allows polarization of differentiating T cells toward TCM. We show Rapa MPs modulate DC function, enhancing secretion of inflammatory cytokines at very low doses, and suppressing function at high doses. While Rapa MP treatment reduced - but did not stop - T cell proliferation in both CD4+ and CD8+ transgenic T cell co-cultures, the expanding CD8+ T cells differentiated to higher frequencies of TCM at low doses of MP Rapa MPs. Lastly, we show in mice that local delivery of Rapa MPs to lymph nodes during vaccination either suppresses or enhances T cell function in response to melanoma antigens, depending on the dose of drug in the depots. In particular, at low Rapa MP doses, vaccines increased antigen-specific TCM, resulting in enhanced T cell expansion measured during subsequent booster injections over at least 100days.
Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.
Authors: Naveed Hassan Akhtar, Beerinder Singh, Allyson J. Ocean, Irene Karpenko, Himisha Beltran, Elizabeta C. Popa, David M. Nanus, Manish A. Shah, Scott T. Tagawa
Journal: Journal of Clinical Oncology (2013)

e15600 Background: The NCI Common Terminology Criteria for Adverse Events (CTCAE) system changed to version 4 in 2009, and several AE categories underwent changes in grading (Gr), including HTN. As many anti-neoplastic agents, particularly those targeting VEGF are associated with HTN, changing in the grading system may result in changes to maximum tolerated or recommended phase II doses in early dose-escalation studies or overall HTN AE reporting across all studies. Methods: We initially reviewed individual patient data of a multicenter phase I/II trial of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma (RCC), which graded AE’s using CTCAE v3. Individual patient (pt) data was reviewed and HTN AE’s were re-graded using CTCAE v4 criteria for up to 12 cycles of therapy on study. A separate (confirmatory) data set in pts with metastatic colorectal cancer (CRC) treated on a phase IIIb study of regorafenib was subsequently analyzed. Results: In the RCC study, only 1 of 23 pts with complete source documents available had stable highest HTN Gr across both CTCAE versions. In the CRC study, 0 of 8 pts had stable Gr. Table 1 compares each individual’s highest CTCAE v3 versus v4 grading of HTN in each study. Across both studies, all pts had HTN AE’s using CTCAE v4. Only 1 pt maintained grading using both versions (Gr 3), with 30 (96.8%) changing grades. Four (12.9%) moved from Gr 0 to Gr 1, fifteen (48.4%) from Gr 0 to Gr 2, five (16.1%) from Gr 1 to Gr 2, one from Gr 1 to Gr 3, and six (19.4%) from Gr 2 to Gr 3. Conclusions: Re-classification of grading in this study demonstrates that only 3.2% maintained stable grading of HTN across systems, with 51.6% increasing by 2 grades. The change in AE reporting criteria has the potential to significantly impact results of clinical trials. This may be particularly important with VEGF-targeted agents, with emerging data pointing towards HTN as a pharmacodynamic marker in pts with RCC, and may affect dosing and AE reporting of other drugs with blood pressure effects. Clinical trial information: NCT00121251, NCT01538680. [Table: see text]
Letter by Treibel et al Regarding Article, “Sex-Related Discordance Between Aortic Valve Calcification and Hemodynamic Severity of Aortic Stenosis: Is Valvular Fibrosis the Explanation?”
Authors: Thomas A. Treibel, Janet A. Gilbertson, Graham W. Taylor, Nigel B. Rendell, Marianna Fontana, Julian D. Gillmore, Philip N. Hawkins, James C. Moon
Journal: Circulation Research (2017)
Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab
Authors: Mary L. Stevenson, Claire Q. F. Wang, Melody Abikhair, Nazanin Roudiani, Diane Felsen, James G. Krueger, Anna C. Pavlick, John A. Carucci
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> Limited therapies are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC). <h3>Objective</h3> To determine the efficacy of programmed cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC. <h3>Design, Setting, and Participants</h3> A single patient with locally advanced cSCC who declined surgery and radiotherapy underwent treatment with pembrolizumab, an anti–PD-1 antibody, at an academic dermatologic surgery section and cancer center. The patient was followed up for clinical and radiologic regression of cSCC. With the use of NanoString to amplify potential biomarkers, immunohistochemistry, and immunofluorescence, the ex vivo expression of PD-1 and a ligand (PD-L2) was assessed in 38 cSCC biopsy specimens from 24 patients with cSCC. Expression of PD-L1 and PD-L2 in the cSCC microenvironment was defined. <h3>Intervention</h3> Pembrolizumab, 2 mg/kg every 3 weeks, for 4 cycles. <h3>Main Outcomes and Measures</h3> Expression of PD-L1 and PD-L2 in the cSCC microenvironment. <h3>Results</h3> In 1 patient with locally advanced cSCC who was treated with pembrolizumab, nearly complete tumor regression was observed after 4 cycles of therapy. The NanoString technology used in 38 cSCC biopsy specimens from 24 patients with cSCC (19 men and 5 women; mean [SD] age, 76.4 [12.2] years) detected increased PD-1 and PD-L2 expression in high-risk cSCC. Immunohistochemical analysis confirmed enhanced expression of PD-1 and its ligands in cSCC with perineural invasion (mean [SEM] expression, 5.06 [1.27];<i>P</i> = .05), superficial cSCC (mean [SEM] expression, 3.58 [1.50];<i>P</i> = .15), organ transplant–associated cSCC (mean [SEM] expression, 3.01 [0.54];<i>P</i> = .005), and infiltrative cSCC (mean [SD] expression, 2.01 [0.30];<i>P</i> = .006) compared with normal skin specimens. In double-label immunofluorescence staining, CD11c<sup>+</sup>, a marker of myeloid dendritic cells, colocalized with PD-L1 and PD-L2 in cSCC lesions. <h3>Conclusions and Relevance</h3> The favorable treatment response combined with significant involvement of PD-1 and PD ligands in cSCC lesions suggests that PD-1 blockade may be a viable therapeutic option for locally advanced cSCC and provides rationale for further investigation in future clinical trials.
Specific detection of Epstein-Barr virus microRNAs in plasma samples from nasopharyngeal carcinoma patients: Correlation with tumor mass assessed by MRI.
Authors: francois-Regis Ferrand, charles-Henry Gatolliat, Francois Bidault, Benjamin Verillaud, Aurore Gelin, anne-Sophie Jimenez-Pailhes, Corinne Amiel, Joel Guigay, Pierre Busson
Journal: Journal of Clinical Oncology (2013)

6079 Background: Epstein-Barr virus (EBV) microRNAs of the BART family can be detected in the plasma of at least a fraction of nasopharyngeal carcinoma (NPC) patients. Our aim was to investigate the specificity of plasma BART detection in NPC patients and the correlation with viral DNA load and/or clinical characteristics. Methods: Hsa miR484 and 4 miR-BARTs (ebv-miR BART 2-5p, 5, 9 and 18) were assessed by RT-PCR following RNA extraction in 37 plasma samples including 20 NPC, 8 non-NPC head and neck squamous cell carcinoma (SCC) patients and 9 healthy EBV carriers. EBV DNA copy numbers (viral load) were measured in the same samples. To explore correlations of BART concentrations with tumor mass, MRI-based volume analysis was designed and performed on a subset of 13 patients with non metastatic NPC. In addition, longitudinal variations of BART concentrations were studied in 9 NPC patients for whom we had sequential plasma samples. Results: The cellular hsa miR-484 was detected in all plasma samples with a slightly higher average concentration in plasma samples from NPC and SCC patients. On the other hand, the miR-BARTs were undetectable or at a very low level in samples from SCC patients and healthy carriers contrasting with a high level in most NPC patients. There was an overall positive correlation between EBVDNA copy numbers and plasma concentrations of each miR-BART. However substantial amounts of plasmatic miR-BARTs were observed in several patients for whom no plasma EBV DNA was detected.Their concentration was apparently not correlated to the initial tumor volume but their longitudinal variations were parallel with clinical evolution in all but one case. Conclusions: To a large extent, detection of plasma miR-BART-2-5p, 5, 9, and 18 is specific of NPC patients. Their concentration does not seem to correlate with tumor mass, at least in localized NPC patients. In a fraction of patients without initial detection of plasma EBV DNA, the kinetics of plasma BARTs may provide informations on early tumor response under treatment and may have prognostic value.
Genetic and Epigenetic Profiling on 7q22 Identifies ATXN7L1 As Candidate Tumor Suppressor in Acute Myelogenous Leukemia
Authors: Anna R Poetsch, Rainer Claus, Jacques Bonnet, Didier Devys, Frank G. Rücker, László Tora, Konstanze Döhner, Hartmut Döhner, Christoph Plass
Journal: Blood (2011)
Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study
Authors: Pallawi Torka, Priyank P. Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala T. Neppalli, Cory Mavis, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2015)
Antibiotics promote the sampling of luminal antigens and bacteria via colonic goblet cell associated antigen passages
Authors: Kathryn A. Knoop, Jenny K. Gustafsson, Keely G. McDonald, Devesha H. Kulkarni, Rachel Kassel, Rodney D. Newberry
Journal: Gut Microbes (2017)

Bacterial translocation is defined as the passage of live bacteria from the gut lumen to distant sites. Gut commensal bacteria translocation has been attributed to 'leakiness', or 'barrier breach' of the intestinal epithelium, allowing live bacteria to cross an inappropriately permeable barrier and disseminate to distant sites. Alternatively, studies suggest dendritic cells directly capture luminal commensal bacteria and transport them to distant sites in the steady-state by extending dendrites between epithelial cells into the lumen. Recently we identified translocation of commensal gut bacteria following antibiotics was associated with the formation of goblet cell associated antigen passages (GAPs) in the colon and dependent upon goblet cells (GCs). The translocation of native gut commensal bacteria resulted in low-level inflammatory responses and potentiated mucosal damage in response to concurrent epithelial injury. Here we extend these observations and demonstrate properties of colonic GAPs and observations supporting their priority in the translocation of colonic commensal bacteria.
The Proteome Analysis of an Imatinib-Resistant Cell Line Identifies Changes in Molecular Chaperones Such as Heat Shock Proteins (Hsp): A Possible New Mechanism of Imatinib Resistance.
Authors: Jean-Max Pasquet, Marion Pocaly, Valérie Lagarde, Béatrice Turcq, Josy Reiffers, Junia V. Melo, Francois-Xavier Mahon
Journal: Blood (2004)
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.
Authors: Simone Ferrero, Daniela Capello, Mirija Svaldi, Michela Boi, Daniela Drandi, Davide Rossi, Gloria Pagliano, Luigia Monitillo, Chiara Lobetti Bodoni, Elisa Genuardi, Rossana Critelli, Serena Bussano, Daniela Barbero, Barbara Mantoan, Elisa Bernocco, Antonio Palumbo, Mario Boccadoro, Gianluca Gaidano, Sergio Cortelazzo, Marco Ladetto
Journal: Blood (2009)
Biomarkers Predicting Acute GvHD and Transplant Outcomes in 120 Consecutive Allogeneic HSCT Recipients
Authors: Raffaella Greco, Francesca Lorentino, Maria Teresa Lupo Stanghellini, Linda Cheyenne Vaccari, Rosamaria Nitti, Maria Chiara Barbanti, Alessandra Forcina, Fabio Giglio, Mara Morelli, Daniele Mannina, Tommaso Perini, Sara Mastaglio, Simona Piemontese, Andrea Angelo Assanelli, Sarah Marktel, Matteo Giovanni Carrabba, Luca Vago, Consuelo Corti, Massimo Bernardi, Fabio Ciceri, Jacopo Peccatori
Journal: Blood (2016)